This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Allergy; inflammatory disease	Bradykinin B2 receptor (BDKRB2; B2R)	A study in mice suggests that antagonizing B2R may help treat edema associated with allergy and inflammation. In a mouse model of allergen-stimulated edema, B2R deficiency led to less edema than that in wild-type controls. Next steps include testing B2R antagonists in animal models of edema. sanofi-aventis Group and Shire plc market the B2R antagonist icatibant (JE049) in Europe to treat angioedema. Abbott Laboratories and Xytis Inc. are developing anantibant (LF16-0687), a B2R antagonist that is in Phase II for shock/trauma.	Unpatented; licensing status not applicable	Oschatz, C. <i>et al. Immunity</i> ; published online Feb. 25, 2011; doi:10.1016/j.immuni.2011.02.008 Contact: Thomas Renné, Karolinska Institute, Stockholm, Sweden e-mail: thomas@renne.net
SciBX 4(11); doi:10.1038/scibx.2011.316 Published online March 17, 2011				